Quarterly ResultAug 5, 2026, 04:09 PM
Sight Sciences Q2 Revenue +20% to $23.4M; Raises 2026 Guidance
AI Summary
Sight Sciences reported strong second-quarter 2026 financial results, with revenue increasing 20% year-over-year to $23.4 million, driven by significant growth in Interventional Dry Eye revenue. The company also improved its net loss by 63% to $4.4 million and reduced cash usage. Based on this performance and business momentum, Sight Sciences raised its full-year 2026 revenue guidance and lowered its adjusted operating expense guidance. Key business developments included FDA clearance for a new surgical system and expanded insurance coverage for its glaucoma products.
Key Highlights
- Q2 2026 revenue increased 20% year-over-year to $23.4 million.
- Interventional Dry Eye revenue grew 704% to a record $2.7 million.
- Net loss improved 63% to $4.4 million, or $0.08 per share.
- Cash and cash equivalents totaled $79.8 million as of June 30, 2026.
- Full-year 2026 revenue guidance raised to $88 million to $92 million.
- Full-year 2026 adjusted operating expense guidance reduced to $92 million to $94 million.
- Received US FDA 510(k) clearance for the OMNI Ultra Surgical System.
- Expanded Interventional Glaucoma coverage by 25 million commercial lives with Aetna.
Price Impact
More from SGHT